

## Uxigril BSS <sup>[1]</sup>

**Uxigril®**. A coated tablet contains 10 mg of Montelukast. A chewable tablet contains 4 mg/ 5 mg of Montelukast. Indications. **Uxigril®** 10 mg indicated for the treatment of asthma as concomitant therapy in patients with persistent asthma, mild to moderate intensity, who are not adequately controlled with inhaled corticosteroids and in whom short-action "on demand" beta agonists do not provide an adequate clinical control. In asthmatic patients with the indication of Montelukast, it can also provide a symptomatic relief of seasonal allergic rhinitis. **Uxigril®** is also indicated for the prophylaxis of asthma where the main component is exercise-induced bronchoconstriction. **Uxigril®** 5 mg indicated for the treatment of asthma as concomitant therapy in patients with persistent asthma, mild to moderate intensity, who are not adequately controlled with inhaled corticosteroids and in whom short-action "on demand" beta agonists do not provide an adequate clinical control. **Uxigril®** 5 mg can also be an alternative treatment option for low-dose inhaled corticosteroids in patients with mild persistent asthma and that do not have a recent history of serious asthma attacks that require the usage of oral corticosteroids or those who have shown that they are not able to use inhaled corticosteroids. **Uxigril®** 4 mg. Indicated for the treatment of asthma as concomitant therapy in patients of 2 to 5 years old with mild to moderate persistent asthma, who are not adequately controlled with inhaled corticosteroids and in whom short action "on demand" beta agonists do not provide an adequate clinical control of asthma. **Uxigril®** 4 mg can also be an alternative treatment option for low-dose inhaled corticosteroids dose in patients of 2 to 5 years old with mild persistent asthma and that do not have a recent history of serious asthma attacks that require the usage of oral corticosteroids or those who have shown that they are not able to use inhaled corticosteroids. **Uxigril®** is also indicated for the prophylaxis of asthma as of 2 years old when the main component is exercise-induced bronchoconstriction. Dose. Adults and adolescents over 15 years old with asthma or asthma and seasonal allergic rhinitis use it as concomitant 10 mg a day. Pediatric patients from 6 to 14 years old, 1 chewable tablet of 5 mg a day. From 2 to 5 years old, 1 chewable tablet of 4 mg/day. Contraindications. Hypersensitivity to the active substance or any of the excipients. Precautions on the usage. Do not use oral montelukast to treat acute asthma attacks. It must not be suddenly replaced by inhaled or oral corticosteroids. In treatments with agents against asthma where montelukast is included, systemic eosinophilia may appear with vasculitis features, which is compatible with the Churg-Strauss Syndrome. **Uxigril®** can be used during pregnancy and breastfeeding only if it is deemed clearly needed. Adverse Effects. Headache, abdominal pain, thirst, upper respiratory tract infection, diarrhea, nausea, vomiting, high levels of transaminases, skin rash, Pyrexia. **CDS 2013.**

Availability of presentations may vary between countries. **Uxigril® 4mg** available for: Curacao and Jamaica. **Uxigril® 5mg** available for: Curacao and Jamaica. **Uxigril® 10mg** available for: Curacao and Jamaica.

---

**Source URL:** <https://www.cac.sandoz.com/en/uxigril-bss>

**Links**

[1] <https://www.cac.sandoz.com/en/uxigril-bss>